1:Sintilimab Plus Chemotherapy

2 trials

Sponsors

Shanghai East Hospital

Conditions

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Unknown Phase

Multicenter, open, single-arm Clinical Study to Evaluate the Efficacy and Safety of Sintilimab Plus Chemotherapy (Cisplatin or Carboplatin+ Paclitaxel) as First-Line Treatment in Patients With Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma (R/M SCCHN)

RecruitingITMCTR1900002567

Shanghai East HospitalRecurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Start: 2019-09-01Updated: 2023-02-20

Multicenter, open, single-arm Clinical Study to Evaluate the Efficacy and Safety of Sintilimab Plus Chemotherapy (Cisplatin or Carboplatin+ Paclitaxel) as First-Line Treatment in Patients With Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma (R/M SCCHN)

RecruitingChiCTR1900025644

Shanghai East HospitalRecurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Start: 2019-09-01Updated: 2019-09-09